<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070470</url>
  </required_header>
  <id_info>
    <org_study_id>16-086D</org_study_id>
    <secondary_id>SCR-004</secondary_id>
    <nct_id>NCT03070470</nct_id>
  </id_info>
  <brief_title>CiPA Phase 1 ECG Biomarker Validation Study</brief_title>
  <official_title>Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spaulding Clinical Research LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Food and Drug Administration (FDA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether exposure response analysis of the electrocardiographic QTc and
      J-Tpeakc intervals in Phase 1 clinical pharmacology studies can be used to confirm that drugs
      that predominantly block the potassium channel encoded by the human ether-à-go-go-related
      gene (hERG) with approximately equipotent late sodium and/or calcium block (&quot;balanced ion
      channel&quot; drugs) do not cause J-Tpeakc prolongation and that drugs that predominantly block
      hERG without late sodium or L-type calcium current block (&quot;predominant hERG&quot; drugs) cause QTc
      prolongation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess whether exposure response analysis of the electrocardiographic QTc and
      J-Tpeakc intervals in Phase 1 clinical pharmacology studies can be used to confirm that
      &quot;balanced ion channel&quot; drugs do not cause J-Tpeakc prolongation and that &quot;predominant hERG&quot;
      drugs cause QTc prolongation. This clinical study consists of 2 parts: a 50-subject parallel
      part (Part 1) and a 10-subject crossover part (Part 2). Up to 74 healthy subjects will be
      enrolled (including 14 potential replacement subjects).

      Part 1 will be a double-blind, randomized, placebo-controlled, 1 period parallel design to
      assess the effect of 4 marketed drugs and 1 placebo on the QTc and J-Tpeakc intervals in 50
      healthy subjects. A parallel design similar to a single or multiple ascending dose (SAD/MAD)
      Phase 1 study will be used that will result in each study drug being administered to 10
      subjects, and placebo to 10 subjects, in 1 period of 3 consecutive days to achieve low and
      high drug exposure.

      Part 2 will be a double-blind, randomized, 2-period crossover design to assess the effect of
      hERG block (dofetilide) versus calcium block (diltiazem) on the QTc and J-Tpeakc intervals in
      10 healthy subjects on Days 1, 2, and 3 (Period 1) and Days 8, 9, and 10 (Period 2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 26, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This clinical study consists of 2 parts:
50 subjects in Part 1 will be randomized to receive one of four drugs (ranolazine, verapamil, lopinavir / ritonavir, chloroquine) or placebo over 3 days.
10 subjects in Part 2 will be randomized to receive one of two treatment sequences (1. dofetilide or 2. diltiazem combined with dofetilide) over 3 days, then after washout, the subjects will receive the other treatment sequence over 3 days. Thus, Part 2 will have a cross-over component.
A maximum of 14 additional replacement subjects may be enrolled.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline J-Tpeakc With &quot;Balanced Ion Channel&quot; Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)</measure>
    <time_frame>3 days</time_frame>
    <description>The primary outcome measure for the &quot;balanced ion channel&quot; drugs (ranolazine, verapamil, lopinavir / ritonavir) is for the upper bound of the 2-sided 90% confidence interval (CI) to be &lt;10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model. Placebo drug concentration was set to 0 (see SAP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline QTc With &quot;Predominant hERG&quot; Blocking Drug (Chloroquine)</measure>
    <time_frame>3 days</time_frame>
    <description>The primary outcome measure for the &quot;predominant hERG&quot; drug (chloroquine) is for the upper bound of the 2-sided 90% CI to be ≥10 msec for the projected placebo-corrected change from baseline QTc effect at the peak plasma level on Day 1 using a linear mixed-effects exposure response model</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)</measure>
    <time_frame>3 days</time_frame>
    <description>It will be assessed whether the projected QTc effect of dofetilide alone is significantly greater (i.e., p&lt;0.05) than the projected QTc effect of the combination of dofetilide + diltiazem. This will be assessed at the dofetilide peak plasma level on Day 3 (computed from the combination of dofetilide + diltiazem) on the pooled dofetilide alone, diltiazem alone, and dofetilide + diltiazem data using a linear mixed effects model.
Subsequently, and if the test is significant for QTc, the same test will be performed to assess calcium block (diltiazem) effects on J-Tpeakc.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Drug-induced QT Prolongation</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranolazine 1500 mg two times per day for 2.5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir / Ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dofetilide and Diltiazem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine 1500 mg orally two times per day for 2.5 days</description>
    <arm_group_label>Ranolazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)</description>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir / Ritonavir</intervention_name>
    <description>Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days</description>
    <arm_group_label>Lopinavir / Ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)</description>
    <arm_group_label>Chloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (administered orally)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dofetilide and Diltiazem</intervention_name>
    <description>In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
    <arm_group_label>Dofetilide and Diltiazem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Subject signs an institutional review board (IRB) approved written informed consent
             and privacy language as per national regulations (e.g., Health Insurance Portability
             and Accountability Act [HIPAA] authorization) before any study related procedures are
             performed.

          2. Subject is a healthy man or woman, 18 to 50 years of age, inclusive, who weighs at
             least 50 kg (110 pounds) and has a body mass index of 18 to 30 kg/m2, inclusive, at
             Screening.

          3. Subject has normal medical history findings, clinical laboratory results, vital sign
             measurements, 12 lead ECG results, and physical examination findings at Screening or,
             if abnormal, the abnormality is not considered clinically significant (as determined
             and documented by the investigator or designee).

          4. Female subjects will be at least 2 years postmenopausal, surgically sterile, or
             practicing 2 highly effective methods of birth control (as determined by the
             investigator or designee; one of the methods must be a barrier technique).

          5. Female subjects must not be pregnant or lactating before enrollment in the study.

          6. Male or female subjects must agree to practice 2 highly effective methods of birth
             control (as determined by the investigator or designee; one of the methods must be a
             barrier technique) from Screening until 30 days after the last dose of study drug.

          7. Subject is highly likely (as determined by the investigator) to comply with the
             protocol defined procedures and to complete the study.

        Exclusion criteria:

          1. Subject has a safety 12 lead ECG result at Screening or Check in with evidence of any
             of the following abnormalities:

               -  QTc using Fridericia correction (QTcF) &gt;430 msec

               -  PR interval &gt;220 msec or &lt;120 msec

               -  QRS duration &gt;110 msec

               -  Second- or third-degree atrioventricular block

               -  Complete left or right bundle branch block or incomplete right bundle branch
                  block

               -  Heart rate &lt;50 or &gt;90 beats per minute

               -  Pathological Q-waves (defined as Q wave &gt;40 msec)

               -  Ventricular pre-excitation

          2. Subject has more than 12 ectopic beats during the 3 hour Holter ECG at Screening.

          3. Subject has a history of unexplained syncope, structural heart disease, long QT
             syndrome, heart failure, myocardial infarction, angina, unexplained cardiac
             arrhythmia, torsade de pointes, ventricular tachycardia, or placement of a pacemaker
             or implantable defibrillator. Subjects will also be excluded if there is a family
             history of long QT syndrome (genetically proven or suggested by sudden death of a
             close relative due to cardiac causes at a young age) or Brugada syndrome.

          4. Subject has a history or current evidence of any clinically significant (as determined
             by the investigator) cardiovascular, dermatologic, endocrine, gastrointestinal,
             hematologic, hepatic, immunologic, metabolic, neurologic, psychiatric, pulmonary,
             renal, urologic, and/or other major disease or malignancy (excluding nonmelanoma skin
             cancer). The investigator may allow exceptions to these criteria (e.g.,
             cholecystectomy, childhood asthma) following discussion with the medical monitor.

          5. Subject has a history of thoracic surgery.

          6. Subject has any condition possibly affecting study drug absorption (e.g., gastrectomy,
             Crohn's disease, irritable bowel syndrome).

          7. Subject has a skin condition likely to compromise ECG electrode placement.

          8. Subject is a female with breast implants.

          9. Subject's laboratory test results at Screening or Check in are outside the reference
             ranges provided by the clinical laboratory and considered clinically significant (as
             determined and documented by the investigator or designee).

         10. Subject's laboratory test results at Screening or Check in indicate hypokalemia,
             hypocalcemia, or hypomagnesemia according to lower limits of the reference ranges
             provided by the clinical laboratory.

         11. Subject's laboratory test results at Screening or Check in are &gt;2 × the upper limit of
             normal (ULN) for alanine aminotransferase or aspartate aminotransferase, &gt;1.5 × ULN
             for bilirubin, or &gt;1.5 × ULN for creatinine.

         12. Subject has a positive test result at Screening for human immunodeficiency virus I or
             II antibody, hepatitis C virus antibodies, or hepatitis B surface antigen.

         13. Subject has a mean systolic blood pressure &lt;100 or &gt;140 mmHg or a mean diastolic blood
             pressure &lt;50 or &gt;90 mmHg at either Screening or Check in. Blood pressure will be
             measured in triplicate after the subject has been resting in a supine position for a
             minimum of 5 minutes.

         14. Subject has a known hypersensitivity to any of the study drugs or related compounds.

         15. Subject has consumed alcohol, xanthine containing products (e.g., tea, coffee,
             chocolate, cola), caffeine, grapefruit, or grapefruit juice within 48 hours before
             dosing or anticipates an inability to abstain from these products throughout the
             duration of the study.

         16. Subject has used nicotine containing products (e.g., cigarettes, cigars, chewing
             tobacco, snuff) within 6 weeks before Screening (self reported).

         17. Subject is unable to tolerate a controlled, quiet, study conduct environment,
             including avoidance of music, television, movies, games, and activities that may cause
             excitement, emotional tension, or arousal during the prespecified time points (e.g.,
             before and during ECG extraction windows).

         18. Subject is unwilling to comply with study rules, including the study-specific diet,
             attempting to void at specified times (e.g., before ECG extraction windows), remaining
             quiet, awake, undistracted, motionless, and supine during specified times, and
             avoiding vigorous exercise as directed.

         19. Subject has a history of consuming more than 14 units of alcoholic beverages per week
             within 6 months before Screening, has a history of alcoholism or
             drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12
             ounces of beer, 4 ounces of wine, or 1 ounce of spirits/hard liquor), or has a
             positive test result for alcohol or drugs of abuse at Screening or Check in.

         20. Subject has used any prescription or nonprescription drugs (including aspirin or
             nonsteroidal anti inflammatory drugs [NSAIDs] and excluding oral contraceptives and
             acetaminophen) within 14 days or 5 half lives (whichever is longer), or complementary
             and alternative medicines within 28 days before the first dose of study drug.

         21. Subject is currently participating in another clinical study of an investigational
             drug or has been treated with any investigational drug within 30 days or 5 half-lives
             (whichever is longer) of the compound.

         22. Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more,
             or received a transfusion of any blood or blood products within 60 days, or donated
             plasma within 7 days before Check in.

         23. Subject has any other condition that precludes his or her participation in the study
             (as determined by the investigator).

         24. Subject is unwilling to have genetic analysis performed or a blood sample collected
             for isolating peripheral blood mononuclear cells (PBMCs).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Sanabria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Clinical Research LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical Research</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vicente J, Zusterzeel R, Johannesen L, Mason J, Sager P, Patel V, Matta MK, Li Z, Liu J, Garnett C, Stockbridge N, Zineh I, Strauss DG. Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the &quot;CiPA&quot; Initiative and Design of a Prospective Clinical Validation Study. Clin Pharmacol Ther. 2018 Jan;103(1):54-66. doi: 10.1002/cpt.896. Epub 2017 Nov 16. Review.</citation>
    <PMID>28986934</PMID>
  </reference>
  <reference>
    <citation>Vicente J. Update on the ECG component of the CiPA initiative. J Electrocardiol. 2018 Nov - Dec;51(6S):S98-S102. doi: 10.1016/j.jelectrocard.2018.08.003. Epub 2018 Aug 7. Review.</citation>
    <PMID>30121123</PMID>
  </reference>
  <results_reference>
    <citation>Vicente J, Zusterzeel R, Johannesen L, Ochoa-Jimenez R, Mason JW, Sanabria C, Kemp S, Sager PT, Patel V, Matta MK, Liu J, Florian J, Garnett C, Stockbridge N, Strauss DG. Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study. Clin Pharmacol Ther. 2019 Apr;105(4):943-953. doi: 10.1002/cpt.1303. Epub 2019 Jan 18.</citation>
    <PMID>30447156</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>January 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Long QT Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Dofetilide</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol and statistical analysis plan released as supplementary materials together with study design and rationale manuscript. ECG analysis plan published together with an update of the CiPA initiative. Annotated ECG waveforms, pharmacokinetic, and other subject level clinical data released as ECGCIPA database in PhysioNet. Clinical study report and analytic code released as supporting information (i.e., study results report) of study results manuscript. See references section.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>January 2018: Study protocol and SAP (doi: 10.1002/cpt.896).
August 2018: ECG analysis plan (doi: 10.1016/j.jelectrocard.2018.08.003).
December 2018: Annotated ECG waveforms and clinical data database (https://physionet.org/physiobank/database/ecgcipa/)
December 2018: Study results report published (doi: 10.1002/cpt.1303)</ipd_time_frame>
    <ipd_access_criteria>Open access</ipd_access_criteria>
    <ipd_url>https://physionet.org/physiobank/database/ecgcipa/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>ECGCIPA</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://physionet.org/physiobank/database/ecgcipa/</doc_url>
      <doc_comment>ECG effects of ranolazine, verapamil, lopinavir+ritonavir, chloroquine, dofetilide, diltiazem, and dofetilide+diltiazem in a small sample size clinical study. The ECGCIPA database contains multi-channel ECG recordings, pharmacokinetic, and clinical data of 60 subjects participating in the CiPA ECG validation study.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://ascpt.onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fcpt.896&amp;file=cpt896-sup-0001-suppinfo1.pdf</doc_url>
      <doc_comment>Study protocol included in the supporting information of the study design and rationale manuscript (Vicente et al. Clin Pharmacol Ther 2018, doi: 10.1002/cpt.896)</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://ascpt.onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fcpt.896&amp;file=cpt896-sup-0003-suppinfo3.pdf</doc_url>
      <doc_comment>Statistical Analysis Plan (SAP) included in the supporting information of the study design and rationale manuscript (Vicente et al. Clin Pharm Ther 2018, doi: 10.1002/cpt.896)</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Study Results Report</doc_type>
      <doc_url>https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.1303</doc_url>
      <doc_comment>Report with full baseline characteristics, adverse events frequencies by treatment, and Consolidated Standards of Reporting Trials (CONSORT) flow diagram, as well as detailed results for multiple ECG biomarkers, as described in the statistical analysis plan is available as Supplementary Materials S1 in the study results manuscript (Vicente et al. Clin Pharmacol Ther 2018 Nov 17. doi: 10.1002/cpt.1303. [Epub ahead of print])</doc_comment>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03070470/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03070470/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>Ranolazine 1500 mg two times per day for 2.5 days
Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days</description>
        </group>
        <group group_id="P2">
          <title>Verapamil</title>
          <description>Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)</description>
        </group>
        <group group_id="P3">
          <title>Lopinavir / Ritonavir</title>
          <description>Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days</description>
        </group>
        <group group_id="P4">
          <title>Chloroquine</title>
          <description>Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo capsules
Placebo: Placebo (administered orally)</description>
        </group>
        <group group_id="P6">
          <title>Dofetilide and Diltiazem</title>
          <description>In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>Ranolazine 1500 mg two times per day for 2.5 days
Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days</description>
        </group>
        <group group_id="B2">
          <title>Verapamil</title>
          <description>Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)</description>
        </group>
        <group group_id="B3">
          <title>Lopinavir / Ritonavir</title>
          <description>Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days</description>
        </group>
        <group group_id="B4">
          <title>Chloroquine</title>
          <description>Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo capsules
Placebo: Placebo (administered orally)</description>
        </group>
        <group group_id="B6">
          <title>Dofetilide and Diltiazem</title>
          <description>In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="8.0"/>
                    <measurement group_id="B2" value="28.2" spread="7.9"/>
                    <measurement group_id="B3" value="32.6" spread="11.1"/>
                    <measurement group_id="B4" value="28.8" spread="8.8"/>
                    <measurement group_id="B5" value="33.3" spread="9.0"/>
                    <measurement group_id="B6" value="33.4" spread="7.2"/>
                    <measurement group_id="B7" value="31.7" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.3" spread="11.1"/>
                    <measurement group_id="B2" value="77.1" spread="10.2"/>
                    <measurement group_id="B3" value="76.2" spread="6.1"/>
                    <measurement group_id="B4" value="72.4" spread="11.3"/>
                    <measurement group_id="B5" value="77.5" spread="15.6"/>
                    <measurement group_id="B6" value="69.5" spread="9.4"/>
                    <measurement group_id="B7" value="75.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116.6" spread="9.5"/>
                    <measurement group_id="B2" value="109.2" spread="6.6"/>
                    <measurement group_id="B3" value="119.4" spread="10.0"/>
                    <measurement group_id="B4" value="114.8" spread="8.1"/>
                    <measurement group_id="B5" value="116.6" spread="6.4"/>
                    <measurement group_id="B6" value="113.4" spread="8.2"/>
                    <measurement group_id="B7" value="115.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="8.7"/>
                    <measurement group_id="B2" value="63.4" spread="6.9"/>
                    <measurement group_id="B3" value="67.3" spread="8.5"/>
                    <measurement group_id="B4" value="66.9" spread="5.5"/>
                    <measurement group_id="B5" value="66.7" spread="9.0"/>
                    <measurement group_id="B6" value="64.2" spread="6.9"/>
                    <measurement group_id="B7" value="65.9" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <units>BPM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="8.9"/>
                    <measurement group_id="B2" value="63.6" spread="9.8"/>
                    <measurement group_id="B3" value="61.3" spread="9.3"/>
                    <measurement group_id="B4" value="59.2" spread="9.5"/>
                    <measurement group_id="B5" value="58.6" spread="5.6"/>
                    <measurement group_id="B6" value="61.9" spread="6.1"/>
                    <measurement group_id="B7" value="60.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PR Interval</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182.4" spread="23.9"/>
                    <measurement group_id="B2" value="178.4" spread="16.2"/>
                    <measurement group_id="B3" value="162.3" spread="16.5"/>
                    <measurement group_id="B4" value="159.1" spread="15.5"/>
                    <measurement group_id="B5" value="164.4" spread="15.0"/>
                    <measurement group_id="B6" value="171.6" spread="19.4"/>
                    <measurement group_id="B7" value="169.7" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QRS Duration</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.1" spread="7.7"/>
                    <measurement group_id="B2" value="82.9" spread="8.2"/>
                    <measurement group_id="B3" value="87.1" spread="5.8"/>
                    <measurement group_id="B4" value="84.7" spread="6.7"/>
                    <measurement group_id="B5" value="85.4" spread="11.5"/>
                    <measurement group_id="B6" value="87.3" spread="9.4"/>
                    <measurement group_id="B7" value="86.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QTc (Fridericia's heart rate corrected QT interval)</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="386.0" spread="20.2"/>
                    <measurement group_id="B2" value="386.5" spread="17.8"/>
                    <measurement group_id="B3" value="383.9" spread="17.1"/>
                    <measurement group_id="B4" value="393.3" spread="20.0"/>
                    <measurement group_id="B5" value="387.1" spread="13.7"/>
                    <measurement group_id="B6" value="397.1" spread="26.1"/>
                    <measurement group_id="B7" value="389.0" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>J-Tpeakc (heart rate corrected J-Tpeak interval)</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227.7" spread="22.7"/>
                    <measurement group_id="B2" value="239.4" spread="22.4"/>
                    <measurement group_id="B3" value="231.0" spread="14.5"/>
                    <measurement group_id="B4" value="238.7" spread="20.3"/>
                    <measurement group_id="B5" value="229.5" spread="24.2"/>
                    <measurement group_id="B6" value="239.7" spread="29.4"/>
                    <measurement group_id="B7" value="234.3" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tpeak-Tend interval</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="7.9"/>
                    <measurement group_id="B2" value="65.1" spread="6.6"/>
                    <measurement group_id="B3" value="65.7" spread="7.9"/>
                    <measurement group_id="B4" value="69.7" spread="8.7"/>
                    <measurement group_id="B5" value="72.5" spread="6.4"/>
                    <measurement group_id="B6" value="70.6" spread="14.8"/>
                    <measurement group_id="B7" value="68.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline J-Tpeakc With &quot;Balanced Ion Channel&quot; Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)</title>
        <description>The primary outcome measure for the &quot;balanced ion channel&quot; drugs (ranolazine, verapamil, lopinavir / ritonavir) is for the upper bound of the 2-sided 90% confidence interval (CI) to be &lt;10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model. Placebo drug concentration was set to 0 (see SAP).</description>
        <time_frame>3 days</time_frame>
        <population>Placebo data was used in the statistical analysis to account for placebo effect. Chloroquine, and dofetilide and diltiazem data were collected but not part of the primary J-Tpeakc analysis. The underlying raw data (available at https://doi.org/10.13026/C2967M) were the input in the statistical analysis. Summary included per PRS review team request.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine 1500 mg two times per day for 2.5 days
Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days</description>
          </group>
          <group group_id="O2">
            <title>Verapamil</title>
            <description>Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)</description>
          </group>
          <group group_id="O3">
            <title>Lopinavir / Ritonavir</title>
            <description>Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days</description>
          </group>
          <group group_id="O4">
            <title>Chloroquine</title>
            <description>Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo (administered orally)</description>
          </group>
          <group group_id="O6">
            <title>Dofetilide and Diltiazem</title>
            <description>In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline J-Tpeakc With &quot;Balanced Ion Channel&quot; Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)</title>
          <description>The primary outcome measure for the &quot;balanced ion channel&quot; drugs (ranolazine, verapamil, lopinavir / ritonavir) is for the upper bound of the 2-sided 90% confidence interval (CI) to be &lt;10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model. Placebo drug concentration was set to 0 (see SAP).</description>
          <population>Placebo data was used in the statistical analysis to account for placebo effect. Chloroquine, and dofetilide and diltiazem data were collected but not part of the primary J-Tpeakc analysis. The underlying raw data (available at https://doi.org/10.13026/C2967M) were the input in the statistical analysis. Summary included per PRS review team request.</population>
          <units>ms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" lower_limit="-66.4" upper_limit="23.6"/>
                    <measurement group_id="O2" value="-7.8" lower_limit="-58.1" upper_limit="11.4"/>
                    <measurement group_id="O3" value="-11.5" lower_limit="-50.7" upper_limit="47.4"/>
                    <measurement group_id="O5" value="-10.9" lower_limit="-81.2" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Upper bound of the 2-sided 90% confidence interval (CI) to be &lt;10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The appropriateness of the linear model will be assessed. Projected estimates will be computed only if the linear model is found acceptable.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>12.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Upper bound of the 2-sided 90% confidence interval (CI) to be &lt;10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The appropriateness of the linear model will be assessed. Projected estimates will be computed only if the linear model is found acceptable.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Upper bound of the 2-sided 90% confidence interval (CI) to be &lt;10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The appropriateness of the linear model will be assessed. Projected estimates will be computed only if the linear model is found acceptable.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline QTc With &quot;Predominant hERG&quot; Blocking Drug (Chloroquine)</title>
        <description>The primary outcome measure for the &quot;predominant hERG&quot; drug (chloroquine) is for the upper bound of the 2-sided 90% CI to be ≥10 msec for the projected placebo-corrected change from baseline QTc effect at the peak plasma level on Day 1 using a linear mixed-effects exposure response model</description>
        <time_frame>3 days</time_frame>
        <population>Ranolazine, verapamil, lopinavir/ritonavir, and dofetilide and diltiazem data were collected but not part of the primary QTc analysis. The underlying raw data (available at https://doi.org/10.13026/C2967M) were the input in the statistical analysis. Median and range summary included per PRS review team request.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine 1500 mg two times per day for 2.5 days
Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days</description>
          </group>
          <group group_id="O2">
            <title>Verapamil</title>
            <description>Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)</description>
          </group>
          <group group_id="O3">
            <title>Lopinavir / Ritonavir</title>
            <description>Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days</description>
          </group>
          <group group_id="O4">
            <title>Chloroquine</title>
            <description>Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo (administered orally)</description>
          </group>
          <group group_id="O6">
            <title>Dofetilide and Diltiazem</title>
            <description>In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline QTc With &quot;Predominant hERG&quot; Blocking Drug (Chloroquine)</title>
          <description>The primary outcome measure for the &quot;predominant hERG&quot; drug (chloroquine) is for the upper bound of the 2-sided 90% CI to be ≥10 msec for the projected placebo-corrected change from baseline QTc effect at the peak plasma level on Day 1 using a linear mixed-effects exposure response model</description>
          <population>Ranolazine, verapamil, lopinavir/ritonavir, and dofetilide and diltiazem data were collected but not part of the primary QTc analysis. The underlying raw data (available at https://doi.org/10.13026/C2967M) were the input in the statistical analysis. Median and range summary included per PRS review team request.</population>
          <units>ms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="17.7" lower_limit="-24.3" upper_limit="71.9"/>
                    <measurement group_id="O5" value="-9.3" lower_limit="-48.3" upper_limit="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Upper bound of the 2–sided 90% CI to be ≥10 msec for the projected placebo-corrected change from baseline QTc effect at the peak plasma level on Day 1 using a linear mixed-effects exposure response model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The appropriateness of the linear model will be assessed. Projected estimates will be computed only if the linear model is found acceptable.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.6</ci_lower_limit>
            <ci_upper_limit>38.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)</title>
        <description>It will be assessed whether the projected QTc effect of dofetilide alone is significantly greater (i.e., p&lt;0.05) than the projected QTc effect of the combination of dofetilide + diltiazem. This will be assessed at the dofetilide peak plasma level on Day 3 (computed from the combination of dofetilide + diltiazem) on the pooled dofetilide alone, diltiazem alone, and dofetilide + diltiazem data using a linear mixed effects model.
Subsequently, and if the test is significant for QTc, the same test will be performed to assess calcium block (diltiazem) effects on J-Tpeakc.</description>
        <time_frame>3 days</time_frame>
        <population>QTc, J-Tpeakc, and drug concentration data from all subjects in the dofetilide and diltiazem arm. Ranolazine, verapamil, lopinavir/ritonavir, chloroquine, and placebo data were collected but not part of this analysis (see SAP). The underlying raw data were the input in the statistical analysis. Summary included per PRS review team request.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine 1500 mg two times per day for 2.5 days
Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days</description>
          </group>
          <group group_id="O2">
            <title>Verapamil</title>
            <description>Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)</description>
          </group>
          <group group_id="O3">
            <title>Lopinavir / Ritonavir</title>
            <description>Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days</description>
          </group>
          <group group_id="O4">
            <title>Chloroquine</title>
            <description>Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo (administered orally)</description>
          </group>
          <group group_id="O6">
            <title>Dofetilide</title>
            <description>Data from the Dofetilide alone period of the crossover part:
In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
          </group>
          <group group_id="O7">
            <title>Diltiazem+Dofetilide</title>
            <description>Data from the diltiazem and dofetilide period of the crossover part:
In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)</title>
          <description>It will be assessed whether the projected QTc effect of dofetilide alone is significantly greater (i.e., p&lt;0.05) than the projected QTc effect of the combination of dofetilide + diltiazem. This will be assessed at the dofetilide peak plasma level on Day 3 (computed from the combination of dofetilide + diltiazem) on the pooled dofetilide alone, diltiazem alone, and dofetilide + diltiazem data using a linear mixed effects model.
Subsequently, and if the test is significant for QTc, the same test will be performed to assess calcium block (diltiazem) effects on J-Tpeakc.</description>
          <population>QTc, J-Tpeakc, and drug concentration data from all subjects in the dofetilide and diltiazem arm. Ranolazine, verapamil, lopinavir/ritonavir, chloroquine, and placebo data were collected but not part of this analysis (see SAP). The underlying raw data were the input in the statistical analysis. Summary included per PRS review team request.</population>
          <units>ms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="2.2" lower_limit="-35.2" upper_limit="64.5"/>
                    <measurement group_id="O7" value="-1.7" lower_limit="-31.9" upper_limit="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 days</time_frame>
      <desc>MedDRA</desc>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>Ranolazine 1500 mg two times per day for 2.5 days
Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days</description>
        </group>
        <group group_id="E2">
          <title>Verapamil</title>
          <description>Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)</description>
        </group>
        <group group_id="E3">
          <title>Lopinavir / Ritonavir</title>
          <description>Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days</description>
        </group>
        <group group_id="E4">
          <title>Chloroquine</title>
          <description>Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo capsules
Placebo: Placebo (administered orally)</description>
        </group>
        <group group_id="E6">
          <title>Dofetilide and Diltiazem</title>
          <description>In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal Distention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dissociation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Burning Sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel Puncture Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jose Vicente, PhD</name_or_title>
      <organization>U.S. Food and Drug Administration</organization>
      <phone>301-796-8442</phone>
      <email>Jose.VicenteRuiz@fda.hhs.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

